| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Biomm S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R$5.00 |
| 52 Week High | R$0 |
| 52 Week Low | R$0 |
| Beta | 0.66 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -10.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOM9 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | -7.1% | -1.3% | 0.7% |
| 1Y | n/a | 2.1% | -4.4% |
Return vs Industry: Insufficient data to determine how BIOM9 performed against the BR Biotechs industry.
Return vs Market: Insufficient data to determine how BIOM9 performed against the BR Market.
Price Volatility
| BIOM9 volatility | |
|---|---|
| BIOM9 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in BR Market | 9.2% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: BIOM9 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BIOM9's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 127 | Heraldo Marchezini | www.biomm.com |
Biomm S.A. operates as a biotechnology company in Brazil. It offers AFREZZA, a human insulin inhalation powder; GHEMAXAN, an enoxaparina sodica; GLARGILIN, a glargine insulin; WOSULIN R, a human insulin; WOSULIN N, an isophane insulin; HERZUMA, a trastuzumab; and CANETA LIFEPEN G PARA APLICACAO DE INSULINA. The company was founded in 2001 and is headquartered in Nova Lima, Brazil.
Biomm S.A. Fundamentals Summary
| BIOM9 fundamental statistics | |
|---|---|
| Market cap | R$430.01m |
| Earnings (TTM) | -R$82.37m |
| Revenue (TTM) | R$124.50m |
3.4x
P/S Ratio-5.2x
P/E RatioIs BIOM9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOM9 income statement (TTM) | |
|---|---|
| Revenue | R$124.50m |
| Cost of Revenue | R$101.74m |
| Gross Profit | R$22.76m |
| Other Expenses | R$105.14m |
| Earnings | -R$82.37m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Mar 27, 2024
| Earnings per share (EPS) | -1.01 |
| Gross Margin | 18.28% |
| Net Profit Margin | -66.16% |
| Debt/Equity Ratio | 157.6% |
How did BIOM9 perform over the long term?
See historical performance and comparison